Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US OKs Orthovita's vertebral fracture trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given Orthovita the green light to begin a pilot study to assess its injectable biomaterial as a treatment for vertebral compression fractures. The synthetic cortical bone void filler, called CORTOSS, will be tested in a trial involving 20 patients at four centres. A European study of the biomaterial in vertebral fractures is already underway (see Clinica No 1017, p 29). Cortoss is currently approved in Europe for the fixation of screws used in patients with weak bone caused by osteoporosis. US trials for this indication are also underway, notes the Malvern, Pennsylvania firm.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts